FrancophonIA/ELRC3.0 huggingface dataset:
English: Common Hypotension◊, Hypertension, Ecchymosis^
Croatian: Često hipotenzija◊, hipertenzija, ekhimoza^
English: Rare Tumour lysis syndrome
Croatian: Rijetko sindrom lize tumora
English: Common Febrile neutropenia^,◊, Pancytopenia◊
Croatian: Često febrilna neutropenija^,◊, pancitopenija◊
English: If pregnancy occurs in a woman treated with lenalidomide, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.
Croatian: Ako žena liječena lenalidomidom zatrudni, liječenje se mora prekinuti i bolesnicu uputiti liječniku specijaliziranom ili iskusnom u teratologiji na pregled i savjetovanje.
English: bone pain, joint pain, tiredness, generalised swelling including swelling of your arms and legs
Croatian: bol u kostima, bol u zglobovima, umor, opće oticanje uključujući oticanje ruku i nogu
English: Infection◊, Urinary tract infection◊,*, Lower respiratory tract infection, Lung infection◊
Croatian: Često infekcija◊, infekcija mokraćnog sustava◊,*, infekcija donjih dišnih puteva, infekcija pluća◊
English: Lenalidomide received by subjects in the placebo arm who crossed over prior to PD upon study unblinding was not considered as a second-line therapy.
Croatian: Lenalidomid, koji su primili ispitanici iz skupine placeba koji su bili prešli u skupinu lenalidomida prije progresije bolesti, po otkrivanju slijepe šifre ispitivanja nije se smatrao terapijom druge linije.
English: In clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls, mainly comprising of basal cell or squamous cell skin cancers.
Croatian: U kliničkim ispitivanjima prethodno liječenih bolesnika s mijelomom koji su primali lenalidomid/deksametazon u usporedbi s kontrolnim skupinama, od kojih je većina imala rak bazalnih ili pločastih stanica kože.
English: Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide in combination therapy, and to a lesser extent in patients with multiple myeloma, taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5).
Croatian: Zbog povećanog rizika od venske tromboembolije u bolesnika s multiplim mijelomom koji uzimaju lenalidomid u kombiniranoj terapiji, a u manjoj mjeri u bolesnika s multiplim mijelomom na monoterapiji lenalidomidom, ne preporučuju se kombinirane peroralne kontracepcijske tablete (vidjeti također dio 4.5).
English: There are no phase III trial experiences with End Stage Renal Disease (ESRD) (CLcr < 30 mL/min, requiring dialysis).
Croatian: Nema iskustava iz ispitivanja faze III s bolesnicima u terminalnom stadiju bubrežne bolesti (Clcr < 30 mL/min, potrebna je dijaliza).
English: The median duration of treatment was 44.0 weeks (min: 0.1, max: 254.9) for len/dex and 23.1 weeks (min: 0.3, max: 238.1) for placebo/dex.
Croatian: Medijan trajanja liječenja iznosio je 44,0 tjedana (min: 0,1, maks: 254,9) za len/deks te 23,1 tjedan (min: 0,3, maks: 238,1) za placebo/deks.
English: Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide.
Croatian: Bolesnici s anamnezom teškog osipa koji je povezan s liječenjem talidomidom ne smiju primati lenalidomid.
English: Cases of allergic reaction/hypersensitivity reactions have been reported in patients treated with lenalidomide (see section 4.8).
Croatian: U bolesnika liječenih lenalidomidom prijavljeni su slučajevi alergijskih reakcija/reakcija preosjetljivosti (vidjeti dio 4.8).
English: • Widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).
Croatian: • široko rasprostranjen osip, visoka tjelesna temperatura, povišeni jetreni enzimi, odstupanja u rezultatima krvnih pretraga (eozinofilija), povećani limfni čvorovi i zahvaćenost drugih tjelesnih organa (reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), poznata i kao sindrom preosjetljivosti na lijek).
English: Complete response and overall response rates in the len/dex arm were also significantly higher than the placebo/dex arm in both studies.
Croatian: Potpuni odgovor i ukupne stope odgovora u skupini koja je primala len/deks bile su također značajno više nego u skupini koja je primala placebo/deks za oba ispitivanja.
English: • Understand that if his female partner becomes pregnant whilst he is taking lenalidomide or shortly after he has stopped taking lenalidomide , he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.
Croatian: • Shvaćaju da u slučaju da partnerica zatrudni za vrijeme njegova liječenja lenalidomidom ili kratko nakon što je prestao uzimati lenalidomid, treba odmah obavijestiti nadležnog liječnika te da se preporučuje partnericu uputiti liječniku specijaliziranom za teratologiju ili s iskustvom u teratologiji zbog procjene i savjeta.
English: • Use in patients with hepatic and/or renal impairment
Croatian: • primjena kod bolesnika s oštećenjem jetre i/ili bubrega
English: Lenalidomidea
Croatian: Lenalidomida
English: When neutrophils
Croatian: Kada broj neutrofila
English: • Wheezing, breathlessness or a dry cough, which may be symptoms caused by inflammation of the tissue in the lungs.
Croatian: • piskanje, nedostatak zraka ili suhi kašalj, što mogu biti simptomi prouzročeni upalom tkiva pluća
English: CI = confidence interval; HR = hazard ratio; max = maximum; min = minimum; NE = not estimable; OS = overall survival; PFS = progression-free survival;
Croatian: CI = interval pouzdanosti; HR = omjer hazarda; maks = maksimum; min = minimum; NP = nije procjenjivo; OS = ukupno preživljenje; PFS = preživljenje bez progresije bolesti;
English: An absence of the intermediate lobe of the lung was observed at 10 and 20 mg/kg/day with dose dependence and displaced kidneys were observed at 20 mg/kg/day.
Croatian: Odsutnost srednjeg režnja pluća ovisna o dozi primijećena je pri dozama od 10 i 20 mg/kg/dan, a poremećaj lokacije bubrega pri dozi od 20 mg/kg/dan.
English: Lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2).
Croatian: Lenalidomid je prisutan u ljudskoj spermi u iznimno niskim koncentracijama tijekom liječenja te se ne može detektirati u ljudskoj spermi 3 dana nakon prekida uzimanja tvari kod zdravih ispitanika (vidjeti dio 5.2).
English: Co-administration of a single 25 mg dose of warfarin had no effect on the pharmacokinetics of lenalidomide.
Croatian: Istodobna primjena pojedinačne doze od 25 mg varfarina nije imala učinka na farmakokinetiku lenalidomida.
English: For patients older than 75 years of age treated with lenalidomide in combination with dexamethasone, the starting dose of dexamethasone is 20 mg once daily on days 1, 8, 15 and 22 of each 28-day treatment cycle.
Croatian: Za bolesnike starije od 75 godina liječene lenalidomidom u kombinaciji s deksametazonom, početna doza deksametazona iznosi 20 mg jedanput na dan, 1., 8., 15. i 22. dana svakog 28-dnevnog ciklusa liječenja.
English: Lenalidomide is structurally related to thalidomide.
Croatian: Lenalidomid je strukturno srodan talidomidu.
English: Newly diagnosed multiple myeloma - in patients who cannot have a bone marrow transplant Lenalidomide Accord is taken with other medicines:
Croatian: Novodijagnosticirani multipli mijelom - u bolesnika u kojih nije moguća transplantacija koštane srži Lenalidomid Accord se uzima s drugim lijekovima:
English: The recommended starting dose is lenalidomide 10 mg orally once daily continuously (on days 1 to 28 of repeated 28-day cycles) given until disease progression or intolerance.
Croatian: Preporučena početna doza lenalidomida iznosi 10 mg peroralno jednom dnevno bez prekida (od 1. do 28. dana u ponavljajućim 28-dnevnim ciklusima), a daje se do napredovanja bolesti ili nepodnošenja liječenja.
English: Therefore, erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.
Croatian: Eritropoetske lijekove ili druge lijekove koji mogu povećati rizik od tromboze, poput hormonskog nadomjesnog liječenja, treba stoga primjenjivati oprezno u bolesnika s multiplim mijelomom koji primaju lenalidomid s deksametazonom.
English: The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with lenalidomide either in combination with melphalan or immediately following high-dose melphalan and ASCT.
Croatian: Rizik od pojave drugih primarnih hematoloških zloćudnih bolesti mora se uzeti u obzir prije početka liječenja lenalidomidom, bilo u kombinaciji s melfalanom ili neposredno nakon visoke doze melfalana i transplantacije autolognih matičnih stanica.
English: This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles; and lenalidomide 10 mg/day orally on days 1 to 21 of repeated 28-day cycles) for induction therapy, up to 9 cycles.
Croatian: Ovo ispitivanje istraživalo je primjenu kombinirane terapije MPR (melfalan 0,18 mg/kg peroralno od 1. do 4. dana u ponavljajućim 28-dnevnim ciklusima; prednizon 2 mg/kg peroralno od 1. do 4. dana u ponavljajućim 28-dnevnim ciklusima; i lenalidomid 10 mg na dan, peroralno od 1.do 21. dana u ponavljajućim 28-dnevnim ciklusima) kao indukcijske terapije, do 9 ciklusa.
English: Duration of the treatment with lenalidomide
Croatian: Trajanje liječenja lenalidomidom
English: Tumour flare reaction and tumour lysis syndrome
Croatian: Reakcija razbuktavanja tumora i sindrom lize tumora
English: For each subsequent drop below 30 x 109/L
Croatian: Za svaki sljedeći pad ispod 30 x 109/L
English: Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide monotherapy as follows: 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles given until disease progression.
Croatian: Bolesnici koji završe 9 ciklusa ili koji ne mogu završiti kombiniranu terapiju zbog nepodnošenja, liječe se monoterapijom lenalidomidom kako slijedi: 10 mg peroralno jednom dnevno, od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima do napredovanja bolesti.
English: Common Respiratory distress◊, Dyspnoea◊
Croatian: Često respiratorni distres◊, dispneja◊
English: ◊ Adverse reactions reported as serious in clinical trials in patients with NDMM who had undergone ASCT * Applies to serious adverse drug reactions only ^ See section 4.8 description of selected adverse reactions a “Pneumonias” combined AE term includes the following PTs: Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis b “Sepsis” combined AE term includes the following PTs: Bacterial sepsis, Pneumococcal sepsis, Septic shock, Staphylococcal sepsis c “Peripheral neuropathy” combined AE term includes the following preferred terms (PTs): Neuropathy peripheral, Peripheral sensory neuropathy, Polyneuropathy d “Deep vein thrombosis” combined AE term includes the following PTs: Deep vein thrombosis, Thrombosis, Venous thrombosis
Croatian: Pneumocystis jirovecii, pneumonija, pneumonija koju uzrokuje Klebsiella, Legionella, mikoplazmatska pneumonija, pneumokokna pneumonija, streptokokna pneumonija, virusna pneumonija, poremećaj funkcije pluća, pneumonitis b “Sepsa” je kombinirani pojam za nuspojave koji uključuje sljedeće preporučene pojmove: bakterijska sepsa, pneumokokna sepsa, septički šok, stafilokokna sepsa c “Periferna neuropatija” je kombinirani pojam za nuspojave koji uključuje sljedeće preporučene pojmove: periferna neuropatija, periferna senzorna neuropatija, polineuropatija d “Duboka venska tromboza” je kombinirani pojam za nuspojave koji uključuje sljedeće preporučene pojmove: duboka venska tromboza, tromboza, venska tromboza
English: Uncommon Angioedema
Croatian: Manje često angioedem
English: There was a higher frequency of grade 4 febrile neutropenia observed (1.7% in MPR+R/MPR+p compared to 0.0% in MPp+p).
Croatian: Opažena je veća učestalost febrilne neutropenije 4. stupnja (1,7 % za MPR+R/MPR+p u usporedbi s 0,0 % za MPp+p).
English: Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone (see sections 4.4 and 4.8).
Croatian: Eritropoetske lijekove ili druge lijekove koji mogu povećati rizik od tromboze, poput hormonskog nadomjesnog liječenja, treba upotrebljavati oprezno u bolesnika s multiplim mijelomom koji primaju lenalidomid s deksametazonom (vidjeti dijelove 4.4 i 4.8).
English: If pregnancy occurs in a partner of a male patient taking lenalidomide, it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.
Croatian: Ako partnerica muškarca koji uzima lenalidomid zatrudni, preporučuje se uputiti je liječniku specijaliziranom ili iskusnom u teratologiji na pregled i savjetovanje.
English: Endpoint len/dex (N=353)
Croatian: Ishod len/deks (N = 353)
English: Therefore breast-feeding should be discontinued during therapy with lenalidomide.
Croatian: Stoga dojenje treba prekinuti za vrijeme liječenja lenalidomidom.
English: Non-invasive SPM comprise basal cell or squamous cell skin cancers.
Croatian: Neinvazivne druge primarne zloćudnne bolesti uključuju rak bazalnih ili pločastih stanica kože.
English: Very Common Pneumonias◊,a, Upper respiratory tract infection, Neutropenic infection, Bronchitis◊, Influenza◊, Gastroenteritis◊, Sinusitis, Nasopharyngitis, Rhinitis
Croatian: Vrlo često pneumonije◊,a, infekcija gornjih dišnih puteva, neutropenijska infekcija, bronhitis◊, influenca◊, gastroenteritis◊, sinusitis, nazofaringitis, rinitis
English: • Educational brochures for Patients
Croatian: • edukacijske knjižice za bolesnike
English: Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)
Croatian: Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
English: Common Sepsis◊,b, Bacteraemia, Lung infection◊, Lower respiratory tract infection bacterial, Bronchitis◊, Influenza◊, Gastroenteritis◊, Herpes zoster◊, Infection◊
Croatian: Često sepsa◊,b, bakterijemija, infekcija pluća◊, bakterijska infekcija donjih dišnih puteva, bronhitis◊, influenca◊, gastroenteritis◊, herpes zoster◊, infekcija◊
English: Lenalidomide must be discontinued for angioedema, grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is suspectedand should not be resumed following discontinuation from these reactions.
Croatian: Lenalidomid se mora prekinuti zbog eksfolijativnog ili buloznog osipa ili u slučaju sumnje na Stevens-Johnsonov sindrom, toksičnu epidermalnu nekrolizu ili reakciju na lijek s eozinofilijom i sistemskim simptomima te se ne smije nastaviti s liječenjem nakon prekida zbog ovih reakcija.
English: In case of neutropenia, the physician should consider the use of growth factors in patient management.
Croatian: U slučaju neutropenije, potrebno je razmotriti primjenu čimbenika rasta u zbrinjavanju bolesnika.
English: Hypomagnesaemia, Hyperuricaemia, Dehydration◊, Hypercalcaemia+
Croatian: Često hipomagnezijemija, hiperuricijemija, dehidracija◊, hiperkalcijemija+
English: Tabulated summary for combination therapy in MM
Croatian: Sažeti tablični prikaz nuspojava za kombiniranu terapiju kod multiplog mijeloma
English: What Lenalidomide Accord contains
Croatian: Što Lenalidomid Accord sadrži
English: The efficacy and safety of lenalidomide maintenance was assessed in two phase 3 multicenter, randomised, double-blind 2-arm, parallel group, placebo-controlled studies: CALGB 100104 and IFM
Croatian: Djelotvornost i sigurnost terapije održavanja lenalidomidom procijenjene su u dva multicentrična randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja faze 3 s dvije paralelne skupine bolesnika: CALGB 100104 i IFM 2005-02.
English: • Pregnancy test regime o Before commencing treatment o During treatment, every 4 weeks except in case of confirmed tubal sterilisation o After finishing treatment
Croatian: • režim testiranja na trudnoću o prije početka liječenja o tijekom liječenja, svaka 4 tjedna, osim u slučaju potvrđenog podvezivanja jajovoda o nakon završetka liječenja
English: The incidence rate of hematologic malignancies, most notably AML, MDS and B-cell malignancies (including Hodgkin's lymphoma), was 1.31 per 100 person-years for the lenalidomide arms and 0.58 per 100 person-years for the placebo arms (1.02 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT).
Croatian: Stopa incidencije hematoloških zloćudnih bolesti, prvenstveno AML, MDS i malignih bolesti Bstanica (uključujući Hodgkinov limfom), bila je 1,31 na 100 osoba-godina za skupinu na lenalidomidu i 0,58 na 100 osoba-godina za skupinu na placebu (1,02 na 100 osoba-godina za bolesnike izložene lenalidomidu nakon transplantacije autolognih matičnih stanica i 0,60 na 100 osoba-godina za bolesnike koji nisu izlagani lenalidomidu nakon transplantacije autolognih matičnih stanica).
English: An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
Croatian: Porast drugih primarnih zloćudnih bolesti primijećen je u kliničkim ispitivanjima prethodno liječenih bolesnika s mijelomom koji su primali lenalidomid/deksametazon (3,98 na 100 osoba-godina) u usporedbi s kontrolnim skupinama (1,38 na 100 osoba-godina).
English: Hypokalaemia◊, Hyperglycaemia, Hypocalcaemia◊, Diabetes mellitus◊, Hypophosphataemia, Hyponatraemia◊, Hyperuricaemia, Gout, Decreased appetite, Weight decreased
Croatian: Često hipokalijemija◊, hiperglikemija, hipokalcijemija◊, dijabetes melitus◊, hipofosfatemija, hiponatrijemija◊, hiperuricijemija, giht, smanjeni apetit, smanjena tjelesna težina
English: • Constipation, diarrhoea, nausea, redness of skin, rashes, vomiting, muscle cramps, muscle aches,
Croatian: • zatvor, proljev, mučnina, crvenilo kože, osipi, povraćanje, grčevi u mišićima, bolovi u mišićima,
English: • Thirst
Croatian: • žeđ
English: The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 17 December 2009 (15.5 months follow up) showed a 62% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.38; 95% CI 0.27, 0.54; p <0.001).
Croatian: Rezultati preživljenja bez progresije bolesti, nakon prethodno planirane interim analize, do zaključnog datuma podataka 17. prosinca 2009. (15,5 mjeseci praćenja) pokazali su 62%-tno smanjenje rizika napredovanja bolesti ili smrti u korist lenalidomida (HR = 0,38; 95 % CI 0,27; 0,54; p <0,001).
English: • Bleeding from the gums, stomach, or bowels
Croatian: • krvarenje iz desni, želuca ili crijeva
English: Recommended coursea once daily a At the physician's discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.
Croatian: Nastaviti s lenalidomidom pri sljedećoj nižoj razini doze jednom dnevno a Ako je neutropenija jedina toksičnost kod bilo koje razine doza, prema liječnikovoj odluci može se dodati čimbenik stimulacije rasta kolonije granulocita (G-CSF) i održavati razinu doze lenalidomida.
English: HR [95% CI], p-value a
Croatian: HR [95 % CI], p-vrijednost a
English: Patients were randomised 1:1 to receive either lenalidomide or placebo maintenance (10 mg once daily on days 1-28 of repeated 28day cycles increased up to 15 mg once daily after 3 months in the absence of dose-limiting toxicity) following 2 courses of lenalidomide consolidation (25 mg/day, days 1-21 of a 28-day cycle).
Croatian: Bolesnici su randomizirani u omjeru 1:1 u skupine u kojima su kao terapiju održavanja primali ili lenalidomid ili placebo (10 mg jednom dnevno, od 1. do 21. dana 28dnevnog ciklusa s povećanjem do 15 mg jednom dnevno nakon 3 mjeseca ako nije postojala toksičnost koja ograničava dozu), poslije 2 ciklusa konsolidacije lenalidomida (25 mg na dan, od 1. do 21. dana 28-dnevnog ciklusa).
English: Haemolysis, Autoimmune haemolytic anaemia, Haemolytic anaemia
Croatian: Manje često hemoliza, autoimuna hemolitička anemija, hemolitička anemija
English: f Median follow-up post-ASCT for all surviving subjects.
Croatian: f Medijan se odnosi na trajanje praćenja poslije transplantacije autolognih matičnih stanica u svih preživjelih ispitanika.
English: The incidence rate of solid tumour SPMs was 1.36 per 100 person-years for the lenalidomide arms and 1.05 per 100 person-years for the placebo arms (1.26 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT).
Croatian: Stopa incidencije solidnih tumora kao druge primarne maligne bolesti bila je 1,36 na 100 osoba-godina za skupine na lenalidomidu i 1,05 na 100 osoba-godina za skupine na placebu (1,26 na 100 osoba-godina za bolesnike izložene lenalidomidu nakon transplantacije autolognih matičnih stanica i 0,60 na 100 osoba-godina za bolesnike koji nisu izlagani lenalidomidu nakon transplantacije autolognih matičnih stanica).
English: Patients were stratified at randomisation by age (≤75 versus >75 years), stage (ISS Stages I and II versus Stage III), and country.
Croatian: Prilikom randomizacije, bolesnici su bili stratificirani prema dobi (≤ 75 naspram > 75 godina), stadiju bolesti (ISS stadij I i II naspram stadij III) te zemlji.
English: • an anti-inflammatory medicine called ‘dexamethasone'
Croatian: • s protuupalnim lijekom pod nazivom ‘deksametazon'
English: The recommended dose of dexamethasone is 40 mg orally once daily on days 1, 8, 15 and 22 of repeated 28-day cycles.
Croatian: Preporučena doza deksametazona je 40 mg peroralno jednom dnevno 1., 8., 15. i 22. dana u ponavljajućim 28-dnevnim ciklusima.
English: Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time.
Croatian: Veća učestalost katarakte zabilježena je u bolesnika koji su primali lenalidomid u kombinaciji s deksametazonom, osobito na dulje vrijeme.
English: Various visceral effects (discoloration, red foci at different organs, small colourless mass above atrioventricular valve, small gall bladder, malformed diaphragm) were also observed in single foetuses.
Croatian: U pojedinih fetusa uočeni su također i različiti učinci na unutarnje organe (promjena boje, crvena žarišta na različitim organima, mala bezbojna masa iznad atrioventrikularnog zaliska, mali žučni mjehur, malformirana dijafragma).
English: 8-year survival rate, % (SE) HR [95% CI]c ; p-valued
Croatian: Stopa preživljenja u 8 godina, % (SE) HR [95 % CI]c; p-vrijednostd Praćenje
English: Repeated oral administration of 1 and 2 mg/kg/day to monkeys for up to 1 year produced reversible changes in bone marrow cellularity, a slight decrease in myeloid/erythroid cell ratio and thymic atrophy.
Croatian: Ponavljane doze od 1 i 2 mg/kg/dan peroralno primjenjivane na majmunima u trajanju do 1 godine dovele su do reverzibilnih promjena u celularnosti koštane srži, blagog pada u omjeru mijeloidnih i eritroidnih stanica i atrofije timusa.
English: • The need to stop Lenalidomide Accord immediately upon suspicion of pregnancy
Croatian: • potreba za prekidom uzimanja lijeka Lenalidomid Accord odmah nakon sumnje na trudnoću